Literature DB >> 22439929

Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer?

Man Yu1, Ian F Tannock.   

Abstract

Pancreatic ductal adenocarcinoma (PDA) responds poorly to chemotherapy. In this issue of Cancer Cell, Provenzano et al. identify hyaluronan as a pivotal determinant of elevated interstitial fluid pressures (IFP) and vascular collapse in PDA. PEGPH20 treatment ablates stromal hyaluronan, normalizes IFP, and increases accessibility of tumor cells to anticancer drugs. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID: 22439929     DOI: 10.1016/j.ccr.2012.03.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  37 in total

1.  Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer.

Authors:  Navid Farr; Yak-Nam Wang; Samantha D'Andrea; Frank Starr; Ari Partanen; Kayla M Gravelle; Jeannine S McCune; Linda J Risler; Stella G Whang; Amy Chang; Sunil R Hingorani; Donghoon Lee; Joo Ha Hwang
Journal:  Int J Hyperthermia       Date:  2017-07-17       Impact factor: 3.914

Review 2.  Developments in preclinical cancer imaging: innovating the discovery of therapeutics.

Authors:  James R W Conway; Neil O Carragher; Paul Timpson
Journal:  Nat Rev Cancer       Date:  2014-04-17       Impact factor: 60.716

3.  Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells.

Authors:  Chenxi Tian; Karl R Clauser; Daniel Öhlund; Steffen Rickelt; Ying Huang; Mala Gupta; D R Mani; Steven A Carr; David A Tuveson; Richard O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

Review 4.  Current Update of a Carboxymethylcellulose-PEG Conjugate Platform for Delivery of Insoluble Cytotoxic Agents to Tumors.

Authors:  Yang Yang; Joseph Bteich; Shyh-Dar Li
Journal:  AAPS J       Date:  2016-11-21       Impact factor: 4.009

5.  Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.

Authors:  Mark J Ernsting; Bryan Hoang; Ines Lohse; Elijus Undzys; Pinjiang Cao; Trevor Do; Bethany Gill; Melania Pintilie; David Hedley; Shyh-Dar Li
Journal:  J Control Release       Date:  2015-03-21       Impact factor: 9.776

Review 6.  Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu.

Authors:  Chandan Kumar-Sinha; Iris Wei; Diane M Simeone
Journal:  Curr Opin Gastroenterol       Date:  2012-09       Impact factor: 3.287

7.  Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model.

Authors:  Weijing Cai; Ranjala Ratnayake; Michael H Gerber; Qi-Yin Chen; Yichao Yu; Hartmut Derendorf; Jose G Trevino; Hendrik Luesch
Journal:  Invest New Drugs       Date:  2018-08-03       Impact factor: 3.850

8.  Odyssey of a cancer nanoparticle: from injection site to site of action.

Authors:  Joseph W Nichols; You Han Bae
Journal:  Nano Today       Date:  2012-12-01       Impact factor: 20.722

9.  Clinical implications of EphB4 receptor expression in pancreatic cancer.

Authors:  Man Li; Zuowei Zhao
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

Review 10.  Fibrosis imaging: Current concepts and future directions.

Authors:  Maike Baues; Anshuman Dasgupta; Josef Ehling; Jai Prakash; Peter Boor; Frank Tacke; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2017-11-20       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.